Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes Life Science Investing
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD Life Science Investing
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy Life Science Investing
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease Life Science Investing
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat Pharmaceutical Investing
Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis Pharmaceutical Investing
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Pharmaceutical Investing
Relay Medical Corp. and AgraFlora Organics International Inc. Form Glow Life Technologies Ltd. for the Development of Medical Technologies in the Cannabis Sector Medical Device Investing
Cardiol Therapeutics Completes Initial Public Offering and the Company’s Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols “CRDL” and “CRDL.WT” Cannabis Investing News